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Abstract 
Background. From an individual participant data (IPD) meta-analysis from four RCTs, comparing HD 
with online-HDF (ol-HDF), previously it appeared that HDF decreases all cause mortality by 14% 
(25;1) and fatal cardiovascular disease (CVD) by 23% (39; 3). Significant differences were not found 
for fatal infections and sudden death. So far, it is unclear, however, whether the reduced mortality 
risk of HDF is only due to a decrease in CVD events and if so, which CVD in particular is prevented, if 
compared to HD. 
 Methods. The IPD-base was used for the present study.  HRs and 95% CIs for cause specific mortality 
overall and in tertiles of the convection volume were calculated using the Cox Proportional hazard 
regression models. Annualized mortality and numbers needed to treat (NNT) were calculated.  
Results. Besides 554 patients dying from CVD, fatal infections and sudden death, 215 participants  
died from ‘other causes’, such as withdrawal from treatment and malignancies.  In this group, the 
mortality risk was comparable between HD and ol-HDF patients, both overall and in tertiles of the 
convection volume. Subdivision of CVD mortality in fatal cardiac, non-cardiac and unclassified CVD, 
showed that ol-HDF was only associated with a lower risk of cardiac casualties [0.64(0.61;0.90)]. 
Annual mortality rates also suggest that the reduction in CVD death is mainly due to a decrease in 
cardiac fatalities, including both ischemic heart disease and congestion. Overall, 32, respectively 75 
patients need to be treated by high volume HDF (HV-HDF) to prevent one all cause, respectively CVD 
death/year. 
Interpretation. The beneficial effect of ol-HDF on all cause and CVD mortality appears mainly due to  
a reduction in fatal cardiac events, including ischemic heart disease as well as congestion.  In HV-HDF 




Compared to the healthy population, hemodialysis (HD) patients have a greatly increased mortality 
risk (1). Since retention of uremic toxins in the middle-molecular weight (MMW) range has been 
implicated in the poor clinical prospects of these patients, removal by convection through high-
permeable (high-flux) dialyzers may improve survival. Three large randomized controlled trials (RCT), 
however, did not demonstrate an overall  favorable effect of high-flux dialyzers over low permeable 
(low-flux) devices, which remove only small  compounds by diffusion (2-4). Yet, in these RCTs a trend 
was observed towards a better clinical outcome for selected patient groups who were treated with 
high-flux HD. Hence, it is possible that the amount of convective transport, which occurs within the 
dialyzer in high-flux HD (<10L/session) (5), was too small to obtain a clinical noticeable effect.  
To retain the diffusive capacity of HD and augment the convection volume, hemodiafiltration (HDF) 
was developed(6). In this modality, plasma water is extracted from the blood, which, however, must 
be replaced by a sterile endotoxin-free substitution fluid.  Originally, replacement fluid was 
administered in bags, which restricted its volume (< 13L/session) (7) and prevented implementation 
on a large scale. With the introduction of modern HDF machines and water treatment systems, which 
allow the online production (ol-HDF) of large amounts of sterile and endotoxin free substitution fluid 
(8), much larger convection volumes (>23L/session) became accessible for every day clinical practice.   
Based on several observational studies (7;9-11) suggesting a superior clinical outcome for patients 
who were treated with HDF, three large RCTs, comparing HD with ol-HDF, were conducted (12-14). 
Despite inconsistent outcomes of the individual studies, a recently published individual participant 
data (IPD) analysis, based on these three studies and a fourth not yet published French investigation, 
indicated that both the all cause and cardiovascular (CVD) mortality risks were significantly reduced 
by ol-HDF (15). These results were confirmed in a latest survey of the French Rein Registry (16). The 
IPD analysis also showed that the mortality risks for infections and sudden death were not different 
for HD and ol-HDF patients. Moreover, it appeared that the relative risk reduction in the all cause and 
CVD mortality risks was greatest for patients who were treated with high volume HDF (HV-HDF).  
Since in our first IPD analysis the total number of deaths was markedly higher than the summed 
mortality from CVD, infections and sudden death, a considerable number of patients died from other 
causes. Hence, it is not quite clear whether the reduction in all cause mortality is exclusively due to a 
decline in fatal CVD events or also to a decrease in non-CVD fatalities. In case of a selected reduction 
in fatal CVD events the question arises whether the beneficial effect of ol-HDF is caused by a 
decrease in cardiac or non-cardiac fatalities, or both.  If, for example, the risk reduction in all cause 
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mortality is largely due to a decrease in fatal cardiac events, it might be helpful for prevention and 
management to know which heart disease in particular benefits from treatment with ol-HDF. Finally, 
from a public health care perspective,  it is also important to know the number of patients needed to 
be treated (NNT) by ol-HDF to prevent one death. The aim of the present study was therefore to 
address these issues and to examine the relationship  between the effects of ol-HDF versus HD on 





MATERIAL AND METHODS 
Study design 
For the present analysis, data were used from the individual participant data (IPD) base of four large 
multicentre RCTs, comparing the effects of ol-HDF with HD in adult patients  (15). A detailed 
description of the study designs, patient eligibility criteria, and treatment procedures of each of the 
individual studies has been provided elsewhere (12-14).   
Study population, study endpoint and follow up  
Besides the subdivision of all cause mortality in CVD mortality, fatal infections and sudden death a 
group ‘other causes’ was created, including death due to malignancies and patients who 
discontinued dialysis treatment, as defined within the individual studies. In addition, we repeated the 
analysis by adding sudden death to the group of CVD mortality(17). Sudden death was defined as a 
sudden unexpected fatality occurring within an hour of symptom onset, or un-witnessed, unexpected 
death in patients to be well in the past 24 hours.  Then we  investigated CVD  mortality, by splitting 
up this fraction in fatal cardiac events, such as myocardial infarction (MI), arrhythmias and ‘chronic 
heart failure/ fluid overload’, non-cardiac fatalities, including stroke and  peripheral arterial disease 
and unclassified CVD mortality, consisting of fatalities which were denoted in the RCTs as CVD, but 
without any further specificity. As congestive heart failure and fluid overload are difficult to 
distinguish in HD patients, in the present analysis both conditions were brought together under the 
heading ‘congestion’.  Subsequently, we  compared the individual cardiac death causes between HD 
and ol-HDF. The HRs for cardiac causes were assessed by calculating first the HR of all cardiac causes 
combined, and subsequently removing  congestion and arrhythmia. Next, we estimated the 
annualized all cause and CVD mortality data/100 patient years in both groups and lastly, the patient 
numbers needed to treat (NNT) by ol- HDF to prevent one HD death/year, overall and in the CVD 
subgroup.    
Data analysis 
Cox proportional hazard regression models with a random effect for study were used to estimate 
hazard ratios (HR) and 95% confidence intervals (CI) comparing the effect of online-HDF versus HD on 
the study endpoints. The dose-response association between achieved convection volume in online-
HDF versus HD and clinical outcomes was examined in tertiles of the actual (on-treatment) delivered, 
1.73m2 body surface area (BSA)-standardized convection volume, and was adjusted for age, sex, 
albumin, creatinin, history of diabetes and previous CVD. All analyses were performed in the 
statistical environment R (version 2.15.3). Two-sided p-values and 95% CI were used for statistical 
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inferences. Annual mortality rates per 100 patient years were calculated by dividing the number of 
deaths by the total follow up in years and multiplying by 100. NNTs/year were calculated by the 





In Table 1 the demographical and clinical patient characteristics, laboratory data and treatment-
related  parameters are summarized. During a mean follow up of 2.5 (1.9-3.0) years, 292 participants 
died of CVD, 150 of infections, 112 of sudden death and 215 of ‘other causes’.  
Ol -HDF and all cause and cause specific mortality 
In Table 2 both the absolute patient numbers and risk ratios are presented. As reported before (15), 
ol-HDF reduced the risk of all cause and CVD mortality by 14% (25;1) and 23% (39;3), respectively. In 
absolute numbers, CVD death accounted for 71% (36/51) of the difference in all cause mortality 
between the two groups. The number of fatalities due to infections, sudden death and the combined 
group ‘other causes’ was comparable. The conclusions for CVD mortality did not materially alter 
when the group sudden death was included in this group.  
Subdivision in tertiles of the convection volume showed a distinct pattern for all cause mortality, CVD 
mortality and sudden death: the larger the convection volume, the lower the associated risk (p for 
trend resp . 0.02, 0.07, 0.04). No such a pattern was observed for the groups consisting of fatal 
infections and ‘other causes’ of death (p respectively 0.15 and 0.74).   
Ol- HDF and cardiovascular disease mortality 
As also shown in Table 2, ol-HDF was associated with a lower risk of cardiac CVD fatalities [HR 
0.64(0.61;0.90)], p=0.01] but not of non-cardiac CVD mortality [HR 0.92 (0.60; 1.43), p=0.73] and 
unclassified CVD mortality [HR 0.90(0.58;1.45), p=0.65]. In absolute numbers, cardiac death 
accounted for 77% (27/36) of the difference in total CVD mortality between the HD and online HDF 
groups.  
High convection volumes appeared to be associated with a lower risk of dying from cardiac causes 
and unclassified CVD than a low convection volume (p for trend respectively 0.03 and 0.05). No such 
a pattern was observed for fatal non-cardiac CVD (p for trend=0.74). The annualized fatal events/100  
patient years are shown in table 3 and figure 1.   
Ol-HDF and pure ‘cardiac’ mortality 
As shown in Table 4, the absolute numbers of myocardial infarction, arrhythmia and congestion were 
38, 15 and 33 in the HD group and 24, 6 and 24, in online HDF, respectively. As for cardiac CVD, the 
lowest HR [0.58(0.36;0.91)] was found for the joint diagnoses myocardial infarction and arrhythmia; 
the addition of congestion yielded a HR of 0.64(0.45;0.90).  
Ol-HDF and numbers needed to treat in tertiles of the convection volume 
Note that the NNTs are presented per year. To prevent one all cause death or one fatal CVD, 61 
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respectively 90 patients need to be treated by ol- HDF.  These figures are 32 and 75, respectively in 






Previously we reported that ol-HDF reduces the all cause mortality risk of dialysis patients by 
14%(25;1) and the CVD mortality risk by 23%(39;3).These data appeared even more pronounced 
[22% (38;2)] and 31%(53;0), respectively] when high convection volumes are applied i.e. HV-HDF 
(15).   
What this study adds 
In the present extended analysis we show first, that the beneficial effect of ol-HDF on survival indeed 
was most prominent for fatal CVD events. Other causes, including a combined group ‘others causes’ 
consisting of 215 fatalities of various diagnoses such as withdrawal from treatment and malignancies, 
did not differ between HD and ol-HDF patients. In absolute numbers, 71% of the lower all cause 
mortality was due to a reduction in fatal CVD. Second, , the risk of pure fatal cardiac CVD differed 
significantly between HD and ol-HDF, while the risk of non-cardiac CVD and un-classified CVD was 
comparable. In absolute numbers, 77% of the lower CVD mortality appeared to result from a 
reduction in cardiac deaths. Third, considering only fatal heart diseases, it appeared that the 
associated risk reduction was not caused by a selective decrease in just one particular fatal heart 
disease, but more likely by a decrease in both ischemic heart disease and congestion. Fourth,  our 
analysis showed that 32, respectively 75 patients need to be treated by HV- HDF to prevent one all 
cause, respectively one CVD death/year.  For comparison, the NNT to prevent one CVD death by anti-
hypertensive treatment in low risk patients with mild hypertension has been estimated 82/10 years 
or 820/year (18). 
In our prior analysis, sudden death  was considered separately because a distinct pattern was 
observed: the larger the convective volume the lower the associated risk. Moreover, not only 
classical CVD events, such as cardiac arrhythmias and severe stroke, may be underlying causes of 
death but also other diagnoses, including lung emboli and septicemia. In this respect, it should be 
noted, however, that, while several arrhythmic triggers, such as large extracellular volume changes, 
electrolyte disturbances and autonomic imbalance in CKD patients with uremic cardiomyopathy, may 
contribute to the risk of sudden cardiac death (SCD), prevention with implantable cardioverter-
defibrillators (ICD) did not show unequivocal beneficial results. Although two meta-analyses (19;20) 
and a recent large propensity-matched mortality analysis (21) suggested a survival advantage of ICD 
implantation in patients with mild CKD, benefit could not be demonstrated in advanced CKD and 
dialysis patients. Based on these data it was speculated that SCD in the latter groups of patients is 
resistant to the effects of ICD. Alternatively, however, it seems possible that sudden death in CKD 
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patients is caused less frequently by lethal arrhythmias, as suggested in several papers (22;23), but 
relatively more often by non-direct cardiac causes, such as severe stroke (13). Unfortunately, scarce 
data are available on the reasons of sudden death in dialysis patients (24). As shown in our study the 
risk of sudden death was similar for HD and ol-HDF patients.  Since sudden death in the general 
population is caused mainly by coronary heart disease-associated causes (17) and should hence be 
considered SCD, in a secondary analysis we included patients who were classified as ‘sudden death’ 
in the group ‘fatal CVD’. This modification did not materially change our main conclusions as outlined 
above.  
Importance of online-HDF on convective transport 
Why is ol-HDF associated with an improved outcome, if compared to HD? As mentioned before, 
retention of MMW and protein-bound uremic toxins have been associated with morbidity and 
mortality in CKD patients (25;26). Until now, however, no specific uremic toxin has been identified 
that is exclusively responsible for the poor clinical prospects of these patients. At this point, however, 
it might be noteworthy to mention that the levels of fibroblast growth factor (FGF) 23, which are 
massively increased in patients with advanced CKD and correlate with left ventricular hypertrophy 
(LVH) (27) and death (28), are highly efficient removed by HDF (29). Hence, lowering of this 
substance may favorably influence the clinical course in these patients. So far, however, definite 
proof is lacking that improvement of the ‘milieu interieur’ will lead to a better clinical outcome.  Yet, 
enhanced removal of MMW and other uremic toxins by an augmented convective transport is an 
appealing explanation for the beneficial effects of ol-HDF on survival.  
Importance of online HDF on intra-dialytic hemodynamic stability 
Alternatively, HDF may improve intra-dialytic hemodynamic instability (30;31), which is the most 
important acute CVD complication in intermittent dialysis therapies and related to end-organ 
ischemia and mortality (32). Since micro-circulatory dysfunction is a common feature in ESKD 
patients (33), intradialytic hypotension (IDH) may further compromise the perfusion and functioning 
of vital organs during treatment. Indeed, well-designed studies have shown that IDH contributes to 
reversible regional myocardial stunning (34;35), splanchnic hypoperfusion and endotoxemia (36),  as 
well as cerebral dysfunctioning (37).  In studies comparing HD with HDF, IDH was mitigated or even 
absent during HDF (38). Interestingly, when cooled dialysate was used in HD, the effect on IDH was 
comparable to HDF (39). Thus, substantial evidence exist for an important effect of thermal balance 
as a contributing factor for the improved hemodynamic stability during HDF. Therefore, apart from 
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enhanced uremic toxin removal by convective transport, HDF may preserve vital organ functioning by 
a superior intra-dialytic hemodynamic stability (40).  
Notably, the results of this analysis were obtained despite the potential negative role of 
high flow fistula on cardiac performance (41). Previously, (42) we described a mean blood flow of 
387 ml/min in HV-HDF (versus 335ml/min in the HD group), which was associated with the 
lowest mortality risk (15). In this respect it is noteworthy to refer to an echocardiographic 
evaluation in 326 CONTRAST participants. From this analysis it appeared that the functional and 
structural changes of the left ventricle which occurred in the group of HD patients, were mitigated or 
virtually absent in patients who were treated with ol-HDF (43).   
Is the reduced risk of cardiac mortality depending on the convection volume? 
Whatever the mechanism(s), the beneficial effect of ol- HDF on mortality appears especially 
pronounced in HV-HDF (15). Therefore, this extended cause specific analysis was also performed in 
tertiles of the convection volume. Apart from a significant trend for all cause, CVD  and pure cardiac 
mortality, a dose-response relation was also observed for unclassified CVD mortality and sudden 
death: the higher the convection volume, the lower the associated risk. No such a pattern was 
observed for fatal infections and the group consisting of ‘other causes’ of death. Assuming that a 
large proportion of the mortality in the groups ‘sudden death’ and ‘non-classified CVD’ originates 
from the heart as well, it appears that the  beneficial effect of  a high convection volume  is indeed 
almost exclusively due to a lower cardiac mortality risk. respectively 
Strengths and limitations 
The strength of this study is the concise and meticulous data collection from four recent RCTs, as 
described previously (15). As a consequence, informative censoring, due to transplantation or 
withdrawal alive from treatment, is negligible. As such, this IPD meta-analysis is unique, and quite 
different from meta-analyses based on aggregated patient data (44-46). By contrast, our IPD meta-
analysis cannot correct for selective inclusion in the individual RCTs, which is obviously a limitation of 
this study.  In addition, we did not calculate changes over time in UF rate, Kt/V, bicarbonate and 
Mg levels, which may be implicated in the life expectancy of our patients (47). However, since not 
all these parameters are available over time in the individual studies and the association of these 
changes on outcome was not the goal of the present study we refrained from such an analysis. 
Other limitations are the differences between trials in terms of study design and methodology, which 
we accounted for as much as possible in our statistical models. Some jargon, however, such as 
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unclassified CVD , which is already hard to interpret in one multicenter RTC, is even more delicate 
when four RCTs from different countries are combined. Furthermore, conclusions on the effects of 
different convection volumes on mortality are derived from post hoc analyses and should hence be 
considered with caution. Finally, the small absolute number of fatal ‘cardiac’ CVD events and hence 
the limited absolute difference between the study groups prevents firm conclusions on the 
protective effects of treatment with ol-HDF.  
Conclusions 
The most important finding of this large scale IPD meta-analysis is the predominant risk reduction of 
fatal CVD in ol-HDF. Other causes of death, including fatal infections and a group consisting of ‘other 
causes’ of death,  such as withdrawal from treatment and malignancies, did not materially differ 
between HD and ol-HDF. The second most important outcome of this study is the finding that the risk 
of fatal non-cardiac CVD events, including stroke and peripheral artery disease, did not differ, while 
ol-HDF was associated with a lower risk of cardiac deaths. The beneficial effect of HV-HDF appears 
especially apparent for this type of fatality. Both a lower risk of ischemic heart disease and 
congestion may play a role. Interestingly, only 32 patients need to be converted from HD to HV-HDF 
to prevent one death from all causes and 75 to prevent one CVD death/year.  
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Table 1: Baseline parameters of study participants   
 
 All (n=2793) HD (n=1393)  HDF (n=1400) 
Patient characteristics 







   Age (years) 64.1 (14.7)  64.4 (14.8) 63.8 (14.3) 
   BMI (after dialysis, kg/m2) 25.2 (4.7) 25.2 (4.6) 25.2 (4.9) 
   Body Surface Area (m2) 1.76 (0.22) 1.77 (0.22) 1.76 (0.22) 
   Systolic blood pressure (mmHg) 137.4 (22.4) 137.5 (22.8) 137.3 (22.1) 
   Diastolic blood pressure (mmHg) 73.7 (13.3) 73.5 (13.6) 73.9 (13.1) 
   Diabetes Mellitus (%) 814 (30) 402 (29) 412 (29) 
   History of CVD (%) 989 (35) 499 (36) 490 (35) 
    
Laboratory data     
   Hemoglobin (g/dl) 11.7 (1.6) 11.7 (1.6) 11.7 (1.6) 
   PTH (ρmol/L) 312.9 (145; 774) 307 (147; 789) 318 (142; 752) 
   Calcium (mg/dl) 39.0 (4.4) 36.0 (4.8) 36.4 (4.0) 
   Bicarbonate (mmol/L) 22.2 (3.5) 22.2 (3.6) 22.3 (3.5) 
   Creatinine (mg/dl), predialysis 8.39 (2.57) 8.42 (2.63) 8.35 (2.51) 
   Phosphate (mg/dl) 4.76 (1.53) 4.71 (1.52) 4.79 (1.53) 
   B-2-microglobulin (mg/L) 27.2 (11.6) 27.7 (11.9) 26.8 (11.3) 
   Albumin (g/dl) 3.98 (0.41) 3.98 (0.41) 3.98 (0.41) 
   Cholesterol (mg/dL) 159 (48) 160 (49) 158 (47) 
   CRP (mg/L) 3.48 (0.90;8.60) 3.47 (0.89; 8.50) 3.50 (0.94; 8.70) 
    
Treatment related parameters     
   Dialysis vintage (months) 33 (15; 64) 34 (15; 65) 32 (14; 64) 
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   Vascular access (AVF) 2376 (85) 1175 (84) 1201 (86) 
   Dialysis single-pool Kt/V 1.52 (0.31) 1.50 (0.30) 1.51 (0.32) 
   Duration of session (min) 233 (20) 233 (20) 233 (20) 
   Blood flow (ml/min) 337 (66) 335 (66) 336 (66) 
 
Values are n (%) for categorical variables, and mean (standard deviation) or median (Q1-Q3) for continuous 
variables. CVD, cardiovascular disease; BP, blood pressure; AVF, arteriovenous fistula; BMI, body mass index.  
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Table 2. Absolute number of deaths in the HD and online HDF groups and differences between 
groups; HR with 95% (CI) in the complete HDF cohort and in tertiles of the convection volume. The 
HD group is used as reference.  
     Online HDF: BSA adjusted convection volume (L/session) 
 all HD HDF HD-
HDF 
Mean 22 <19 19-23 >23 
ALL CAUSES^ 769 410 359 51 0.86 (0.75;0.99) 0.83 (0.66;1.03) 0.93(0.75;1.16) 0.78(0.62;0.98) 
All CVD** 292 164 128 36 0.77 (0.61;0.97) 0.92(0.65;1.30) 0.71(0.49;1.03) 0.69(0.47;1.00) 
    Cardiac^ 135 81 54 27 0.64(0.61;0.90) 0.95(0.65;1.39) 0.69(0.46;1.04) 0.70(0.47;1.05) 
    non-cardiac* 80 42 38 4 0.92(0.60;1.43) 0.64(0.26;1.55) 1.22(0.67;2.23) 0.86(0.47;1.78) 
    Unclassified^ 77 41 36 5 0.90(0.58;1.42) 0.82(0.25;1.50 1.20(0.66;2.20) 0.85(0.46;1.55) 
INFECTIONS* 150 77 73 4 0.94 (0.68;1.30) 1.50(0.92;2.46) 0.97(0.54;1.74) 0.62(0.32;1.19) 
SUDDEN death^ 112 56 56 0 0.99 (0.68;1.43) 1.09(0.69;1.74) 1.04(0.63;1.70) 0.69(0.39;1.20) 
OTHER causes* 215 113 102 9 0.88 (0.68;1.13) 0.67(0.45;1.01) 1.13(0.77;1,67) 0.87(0.59;1.30) 
CVD including 
sudden death^ 
404 220 184 36 0.81 (0.65;1.00) 0.93(0.66;1.30) 0.82(0.59;1.14) 0.72(0.51;1.00) 
HR: hazard rate, CI: confidence interval, BSA: body surface area, HD: hemodialysis, HDF: hemodiafiltration, CVD: 
cardiovascular disease.  Cardiac CVD includes:  myocardial infarction, arrhythmia and congestion; non-cardiac 
CVD includes: stroke, peripheral arterial disease; unclassified includes: CVD, but without any further specificity. 





Table 3. Annualized all cause and CVD mortality/100 patient years and NNT/year in the complete 
online HDF cohort and in tertiles of the convection volume. The HD group is used as reference. 
 HD Online HDF: BSA adjusted convection volume (L/session) 
 n.a. Mean 22 <19 19-23 >23 
All cause/100 PY 12.10 10.45 10.94 10.78 8.96 
CVD/100 PY 4.84 3.73 4.28 3.66 3.51 
NNT/year: overall/CVD n.a. 61/90 86/178 75/84 32/75 
HD: hemodialysis, HDF: hemodiafiltration, NNT: number needed to treat, BSA: body surface are, CVD: 






Table 4. Absolute number of cardiac deaths in the HD and online HDF groups and differences 
between groups;  HR and 95% (CI) for pure cardiac CVD mortality. The HD group is used as 
reference  
 
Cardiac cause HD HDF HD - HDF HR (95% CI) 
MI, AR, congestion 86 54 32 0.64 (0.45;0.90) 
MI, AR 53 30 23 0.58 (0.36;0.91) 
MI  38 24 14 0.61 (0.37;1.02) 
Adjusted  for age, sex, albumin, creatinine, history of cardiovascular disease, history of diabetes. HD: 
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